Bile Microbiome Signatures Associated with Pancreatic Ductal Adenocarcinoma Compared to Benign Disease: A UK Pilot Study

被引:5
作者
Merali, Nabeel [1 ,2 ,3 ]
Chouari, Tarak [2 ,3 ]
Terroire, Julien [4 ,5 ]
Jessel, Maria-Danae [3 ]
Liu, Daniel S. K. [6 ]
Smith, James-Halle [7 ]
Wooldridge, Tyler [3 ]
Dhillon, Tony [3 ]
Jimenez, Jose I. [8 ]
Krell, Jonathan [6 ]
Roberts, Keith J. [7 ]
Rockall, Timothy A. [1 ]
Velliou, Eirini [9 ]
Sivakumar, Shivan [10 ]
Giovannetti, Elisa [11 ,12 ]
Demirkan, Ayse [4 ,5 ]
Annels, Nicola E. [3 ]
Frampton, Adam E. [1 ,2 ,3 ,6 ]
机构
[1] Royal Surrey Cty Hosp NHS Fdn Trust, Minimal Access Therapy & Training Unit MATTU, Leggett Bldg, Guildford GU2 7XX, England
[2] Royal Surrey Cty Hosp NHS Fdn Trust, Dept Hepatopancreato Biliary HPB Surg, Guildford GU2 7XX, England
[3] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Sect Oncol, Guildford GU2 7WG, England
[4] Univ Surrey, Surrey Inst People Centred AI, Guildford GU2 7XH, England
[5] Univ Surrey, Fac Hlth & Med Sci, Dept Clin & Expt Med, Sect Stat Multi, Guildford GU2 7WG, England
[6] Imperial Coll London, Div Canc, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England
[7] Univ Birmingham, Queen Elizabeth Hosp Birmingham, Coll Med & Dent Sci, Hepatobiliary & Pancreat Surg Unit, Birmingham B15 2TH, England
[8] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England
[9] Univ Coll London UCL, Ctr 3D Models Hlth & Dis, Dept Targeted Intervent, Div Surg & Intervent Sci, London W1W 7TY, England
[10] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham Med Sch, Oncol Dept, Birmingham B15 2TT, England
[11] VU Univ Med Ctr Canc Ctr Amsterdam, Dept Med Oncol, NL-1081 HV Amsterdam, Netherlands
[12] Fdn Pisana Sci, AIRC Start Unit, Canc Pharmacol Lab, San Giuliano Terme PI, I-56017 Pisa, Italy
关键词
pancreatic cancer; microbiome; 16S rRNA gene; bile; biomarker; TUMOR MICROBIOME; CANCER; GEMCITABINE;
D O I
10.3390/ijms242316888
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) has a very poor survival. The intra-tumoural microbiome can influence pancreatic tumourigenesis and chemoresistance and, therefore, patient survival. The role played by bile microbiota in PDAC is unknown. We aimed to define bile microbiome signatures that can effectively distinguish malignant from benign tumours in patients presenting with obstructive jaundice caused by benign and malignant pancreaticobiliary disease. Prospective bile samples were obtained from 31 patients who underwent either Endoscopic Retrograde Cholangiopancreatography (ERCP) or Percutaneous Transhepatic Cholangiogram (PTC). Variable regions (V3-V4) of the 16S rRNA genes of microorganisms present in the samples were amplified by Polymerase Chain Reaction (PCR) and sequenced. The cohort consisted of 12 PDAC, 10 choledocholithiasis, seven gallstone pancreatitis and two primary sclerosing cholangitis patients. Using the 16S rRNA method, we identified a total of 135 genera from 29 individuals (12 PDAC and 17 benign). The bile microbial beta diversity significantly differed between patients with PDAC vs. benign disease (Permanova p = 0.0173). The separation of PDAC from benign samples is clearly seen through unsupervised clustering of Aitchison distance. We found three genera to be of significantly lower abundance among PDAC samples vs. benign, adjusting for false discovery rate (FDR). These were Escherichia (FDR = 0.002) and two unclassified genera, one from Proteobacteria (FDR = 0.002) and one from Enterobacteriaceae (FDR = 0.011). In the same samples, the genus Streptococcus (FDR = 0.033) was found to be of increased abundance in the PDAC group. We show that patients with obstructive jaundice caused by PDAC have an altered microbiome composition in the bile compared to those with benign disease. These bile-based microbes could be developed into potential diagnostic and prognostic biomarkers for PDAC and warrant further investigation.
引用
收藏
页数:13
相关论文
共 45 条
  • [41] Extensive (subtotal) distal pancreatectomy for pancreatic ductal adenocarcinoma: a propensity score matched cohort study of short- and long-term outcomes compared with those of conventional distal pancreatectomy
    Yusuke Watanabe
    Kohei Nakata
    Yasuhisa Mori
    Noboru Ideno
    Naoki Ikenaga
    Takao Ohtsuka
    Masafumi Nakamura
    Langenbeck's Archives of Surgery, 2022, 407 : 1479 - 1488
  • [42] Endovascular implantation of iodine-125 seed strand combined and stent placement for locally advanced pancreatic ductal adenocarcinoma with vascular invasion: a prospective single-arm pilot study
    Wu, Linlin
    Zhang, Yanbo
    Zhang, Zihan
    Li, Fengfeng
    Luo, Jianjun
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (05) : 427 - 434
  • [43] CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study
    Toshima, Fumihito
    Watanabe, Ryosuke
    Inoue, Dai
    Yoneda, Norihide
    Yamamoto, Tatsuya
    Sasahira, Naoki
    Sasaki, Takashi
    Matsuyama, Masato
    Minehiro, Kaori
    Tateishi, Ukihide
    Gabata, Toshifumi
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2021, 217 (06) : 1353 - 1364
  • [44] Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
    Labori, Knut J.
    Katz, Matthew H.
    Tzeng, Ching W.
    Bjornbeth, Bjorn A.
    Cvancarova, Milada
    Edwin, Bjorn
    Kure, Elin H.
    Eide, Tor J.
    Dueland, Svein
    Buanes, Trond
    Gladhaug, Ivar P.
    ACTA ONCOLOGICA, 2016, 55 (03) : 265 - 277
  • [45] The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study
    Huang, Lei
    Yang, Hui
    Chen, Kaidi
    Yuan, Jing
    Li, Jie
    Dai, Guanghai
    Gu, Mancang
    Shi, Yan
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (12):